Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD44 antagonizing oHSV promotes the formation of tertiary lymphoid structures and improves anti-tumor immunity

ABSTRACT: Oncolytic HSV (oHSV) therapy is currently approved for melanoma (in USA and EU) and recurrent brain tumors (conditional approval in Japan). To understand opportunities to improve therapeutic index, we analyzed transcriptomic changes in patients with recurrent brain tumors before and after treatment with CAN-3110. Gene set pathway analysis showed a significant enrichment of glycosaminoglycan (GAG) synthesis and extracellular matrix (ECM) interactions in patients after oHSV treatment. CD44 is a cell surface receptor that engages with receptors and also with ECM to orchestrate cell-ECM interactions. To evaluate the significance of the multiple CD44 regulated ECM interactions during virotherapy, we created an oHSV that encodes for the secreted extracellular CD44 (Ox44) which functions as a decoy receptor to inhibit cell-ECM interactions. Treatment with Ox44 also destabilized SLC7A11 (xCT) inducing oxidative stress and inhibiting antiviral STING signaling in infected tumor cells. Interestingly the ensuing increased viral burst and immunogenic cell death amplified innate immune activation in immune cells. This correlated with the induction of inflammatory cytokines like interferon (IFN) and IL-1 and the formation of tertiary lymphoid structures (TLS) in intracranial tumors. Single cell sequencing uncovered that Ox44-treated tumors had increased antigen presentation and increased T cell diversity and anti-tumor efficacy. To our knowledge, this is the first report to show that CD44 presents a barrier to both oncolytic virus replication as well as anti-tumor immunity.

ORGANISM(S): Mus musculus

PROVIDER: GSE314573 | GEO | 2026/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

oHSV Drives Tertiary Lymphoid Structure Boosting Oral Cancer Immunotherapy

Project description:The formation of TLSs induced by oncolytic virus treatment can enhance the anti-tumor response of oral cancer. Therefore, oncolytic virotherapy in vivo is a good strategy. To understand the mechanism of post-treatment changes, we collected oHSV-treated tumors for RNA-seq.

2025-01-08 | GSE262913 | GEO

Single cell RNA-sequencing of M002 oHSV-treated murine glioblastoma

Project description:In this study, we evaluated the effects of M002 oncolytic herpes simplex virus (oHSV) in a syngeneic intracranial glioblastoma stem cell model. We harvested tumor-bearing mouse brain tissue 45 days post-injection of M002 oHSV and performed single-cell RNA-sequencing (scRNA-seq).

2024-12-03 | GSE246895 | GEO

oHSV-mediated JAG1 blockade induces glioma senescence-associated secretory phenotype to increase macrophage activation and sensitize to cetuximab-mediated senolysis

Project description:Oncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells and tumor-associated macrophages (TAMs), and its expression correlated with a worse prognosis, we engineered a JAG1-antagonizing oHSV (OncoD-0J1) and interrogated its impact on the tumor and myeloid TME. OncoD-0J1 antagonized JAG1-mediated Notch signaling and had a significant therapeutic advantage in vivo, which relied on Notch signature in tumor cells. Kinome profiling revealed that OncoD-0J1 treatment suppressed CDK1, resulting in a G2/M cell cycle checkpoint as seen by cell cycle analysis. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 accumulation, autophagosome accumulation, and senescence-associated beta-galactosidase activity. This resulted in increased production of inflammatory chemokines and DAMPs such as IL-1β and extracellular ATP. RNA sequencing of murine macrophages co-cultured with infected human tumor cells showed enrichment of chemotactic and pro-inflammatory pathways as well as increased Fc receptor activation following OncoD-0J1 infection. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from infected tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OncoD-0J1 treatment. Senescent cells showed heightened EGFR activation as a mechanism to escape death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.

2025-12-11 | GSE304030 | GEO

oHSV-mediated JAG1 blockade induces glioma senescence-associated secretory phenotype to increase macrophage activation and sensitize to cetuximab-mediated senolysis II

2025-12-05 | GSE303831 | GEO

oHSV-mediated JAG1 blockade induces glioma senescence-associated secretory phenotype to increase macrophage activation and sensitize to cetuximab-mediated senolysis III

2025-12-11 | GSE303833 | GEO

oHSV-mediated JAG1 blockade induces glioma senescence-associated secretory phenotype to increase macrophage activation and sensitize to cetuximab-mediated senolysis I

2025-12-11 | GSE303830 | GEO

IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity

Project description:Identification of IDH mutations has uncovered the crucial role played by metabolism in glioma-genesis. Oncolytic herpes virus (oHSV) therapy initiates direct tumor debulking by tumor lysis and also activates antitumor immunity however little is known about the role of glioma metabolism in determining oHSV efficacy. Here we identified that oHSV therapy rewired central carbon metabolism with increased glucose utilization towards oxidative phosphorylation and shuttled glutamine towards reductive carboxylation in IDH wildtype (wt) glioma. The switch in metabolism resulted in increased lipid synthesis, and cellular ROS. PKC induced ACSL4 in oHSV treated cells led to lipid peroxidation and ferroptosis. Ferroptosis was critical to launch an antitumor immune response important for efficacy. Mutant IDH (IDHR132H) gliomas are incapable of reductive carboxylation and hence ferroptosis. Pharmacological blockade of IDHR132H induced ferroptosis and antitumor immunity. This study provides a rationale to treat high grade IDHR132H glioma patients under oHSV treatment with IDHR132H inhibitor.

2025-04-02 | GSE289317 | GEO

FEC + OV treatment of TNBC tumors

Project description:E0771 subcutaneous tumors in C57/Bl6 mice were treated with saline, FEC (chemotherapy), oHSV-1 (oncolytic virus) or FEC + oHSV-1

2021-06-21 | GSE152698 | GEO

Transcription profiling of human MPNST cancer cells infected with G207 an oncolytic HSV

Project description:We used microarrays to identify genes regulated during oncolytic HSV infection. Oncolytic herpes simplex viruses (oHSV) are promising anticancer therapeutics. We sought to identify alterations in gene expression during oHSV infection of human cancer cells. Human malignant peripheral nerve sheath tumor (MPNST) cells were infected with G207, an ICP34.5-deleted oHSV previously evaluated in clinical trials. G207-infected cells demonstrated massive degradation of cellular mRNAs, while a subset were upregulated. A gene signature of 21 oHSV-induced genes contained 7 genes known to be HSV-induced. Go ontology classification revealed that a majority of upregulated genes are involved in Jak/STAT signaling, transcriptional regulation, nucleic acid metabolism, protein synthesis and apoptosis. Ingenuity-defined functional networks highlighted nodes for AP-1 subunits and interferon signaling via STAT1, SOCS1, SOCS3 and RANTES. Upregulation of SOCS1 correlated with sensitivity of MPNST lines to G207 and depletion of SOCS1 reduced virus replication >1-log. The transcriptome of oHSV-induced genes may predict oncolytic efficacy and provides rationale for next generation oncolytics. Experiment Overall Design: 5 human MPNST cancer cell lines were infected with G207 or mock infected for 6 hours followed by RNA extraction and hybridization on Affymetrix microarrays.

2008-06-16 | E-GEOD-8717 | biostudies-arrayexpress

Single cell RNA-sequencing of C134 oHSV-treated murine medulloblastoma

Project description:Here, we studied the effects of oHSV C134 in two syngeneic medulloblastoma mouse models, one that aligns with the sonic hedgehog (SHH) subtype (MYCN) and another that aligns with tumors of the group 3 subtype (CMYC).We harvested tumor tissue two and six days post-injection of C134 and performed single cell RNA-sequencing (scRNA-seq).

2023-07-27 | GSE200008 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data